New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTATHX, CYTX, NBS, CAPR, PBMD, CELG, HART, BLUE, FATEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
News For BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:36 EDTCELGCelgene names Alles, Fouse to board of directors
Subscribe for More Information
February 10, 2016
07:07 EDTCYTXCytori to present two year Scleroderma data at Systemic Sclerosis World Congress
Subscribe for More Information
06:33 EDTCELGCelgene expands use of Medidata's cloud platform
Subscribe for More Information
February 8, 2016
07:01 EDTCYTXCytori Therapeutics reports interim data on U.S. Phase II osteoarthritis trial
Cytori Therapeutics announced the top-line data as part of the pre-specified partial unblinding of 24 week follow up data from the company's ACT-OA trial. The trial is a U.S. phase II randomized, double-blind, placebo controlled trial designed to evaluate the safety and feasibility at 48 weeks of a single intra-articular knee injection of the ECCO-50 cellular therapeutic in patients with chronic knee pain due to osteoarthritis. "Key endpoints and trends observed thus far suggest that a beneficial effect may be attributable to a single intra-articular administration of ECCO-50 in patients with osteoarthritis of the knee," said Dr. Marc H. Hedrick, President and CEO. "The full 48 week data set is the next important milestone in this program. While we continue to move our clinical pipeline along, the company will remain intensely focused on bringing to market our lead therapeutic for scleroderma which is currently in phase III." The primary goal of the ACT-OA trial is to help determine: (1) safety and feasibility of ECCO-50 for osteoarthritis, (2) provide dosing guidance and (3) explore key trial endpoints useful for a phase III trial. As a proof of concept trial, ACT-OA was not sized or powered for statistical significance in any of the endpoints. The purpose of the interim 24 week partial unblinding in this trial is to provide early data that will facilitate key regulatory and business development discussions and provide better understanding of the therapeutic mechanism of action that may impact other clinical programs. The interim analysis pre-specifies the evaluation of a number of patient reported outcomes important in patients with osteoarthritis of the knee. A total of 94 patients were treated in the trial, 31 received a high dose of ECCO-50. Patients, providers and Cytori personnel remain blinded to individual patient treatment allocation and patient subgroup outcomes.
February 7, 2016
20:36 EDTCELGOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
12:38 EDTCELGCelgene, Gilead too cheap to ignore, could rise 30% in next year, Barron's says
Shares of Celgene (CELG) and Gilead (GILD) could advance 30% over the next year, Barron's contends in a feature article. Concerns over the two firms having too much revenue concentrated in just a few key products are legitimate but "solvable," and their shares now look "too cheap to ignore" amid the general rout in biotech names, the publication says. Reference Link
February 5, 2016
09:26 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:04 EDTCELGCelgene resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTCELGCelgene reinitiated with a Market Perform at Leerink
Subscribe for More Information
10:36 EDTCELGCelgene February weekly calls activity attributed to takeover speculation
Subscribe for More Information
10:31 EDTCELGRumor: Celgene strength attributed to takeover speculation
Shares of Celgene (CELG) are moving higher amid renewed speculation Bristol-Meyers (BMY) is interested in acquiring the company.
February 3, 2016
13:49 EDTATHXAthersys to host research and development day
Research and Development Day to be held in New York on February 4 at 4:30 pm. Webcast Link
10:00 EDTBLUEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Capella Education (CPLA) initiated with an Outperform at Credit Suisse... DeVry (DV) initiated with an Outperform at Credit Suisse... Gilead (GILD) initiated with a Buy at Standpoint Research... Grand Canyon (LOPE) initiated with a Neutral at Credit Suisse... Hannon Armstrong (HASI) initiated with an Equal Weight at Morgan Stanley... Houghton Mifflin (HMHC) initiated with an Outperform at Credit Suisse... Mediaset (MDIUY) initiated with a Buy at Jefferies... Palo Alto (PANW) initiated with a Buy at Maxim... Splunk (SPLK) initiated with a Buy at Maxim... Strayer (STRA) initiated with a Neutral at Credit Suisse... Tableau (DATA) initiated with a Sell at Maxim... Tesla (TSLA) initiated with a Sell at Berenberg... WisdomTree (WETF) initiated with an Outperform at Northland... bluebird bio (BLUE) initiated with an Outperform at Leerink.
08:57 EDTCELGPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
08:02 EDTBLUEbluebird bio initiated with an Outperform at Leerink
Subscribe for More Information
07:15 EDTCYTXCytori says Cytori Cell Therapy 'safe' and 'effective' in EU Phase 1 ED trial
Subscribe for More Information
February 2, 2016
08:53 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
January 29, 2016
08:17 EDTCELGCelgene fundamentals, valuation compelling, says Cantor
Cantor says that Celgene's sell-off was not caused by its results, but by other factors such as currency fluctuations. The firm says that the company's EPs growth remains strong, while its pipeline can enable the company to keep growing over the longer term. The firm continues to expect the company to generate strong cash flow, and it reiterates a $163 price target and Buy rating on the shares.
08:06 EDTCELGUBS said no change to bullish stance on Celgene
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use